{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T15:17:52Z","timestamp":1793891872318,"version":"4.8.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T00:00:00Z","timestamp":1675123200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T00:00:00Z","timestamp":1675123200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009230","name":"Landstinget i Uppsala l\u00e4n","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009230","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Br\u00f6stcancerf\u00f6rbundet"},{"DOI":"10.13039\/501100007051","name":"Uppsala University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007051","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Difficulty in preoperatively assessing the risk for occult invasion or surgery that precludes future accurate axillary mapping in patients with ductal cancer in situ (DCIS) account for overutilization of SLND.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Prospective, multicenter, cohort study, including women with any DCIS planned for mastectomy or DCIS grade 2 and\u2009&gt;\u200920\u00a0mm, any DCIS grade 3, any mass-forming DCIS and any planned surgery. Patients received an interstitial SPIO injection during breast surgery, but no upfront SLND was performed. If invasion was identified on final pathology, delayed SLND (d-SLND) was performed separately with the coadministration of isotope \u00b1 blue dye (BD). Study outcomes were proportion of upfront SLNDs that were avoided, detection rates during d-SLND, and impact on healthcare costs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>In total, 78.7% of study participants (<jats:italic>N\u2009<\/jats:italic>=\u2009254, mean age 60\u00a0years, mean DCIS size 37.8\u00a0mm) avoided upfront SLND. On d-SLND (median 28\u00a0days, range 9\u201346), SPIO outperformed Tc<jats:sup>99<\/jats:sup> with (98.2% vs. 63.6%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) or without BD (92.7% vs. 50.9%, <jats:italic>p\u2009<\/jats:italic>&lt;\u20090.001) and had higher nodal detection rate (86.9% vs. 32.3%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001) and with BD (93.9% vs. 41.4%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). Only 27.9% of all SLNs retrieved were concordant for Tc<jats:sup>99<\/jats:sup> and SPIO. Type of breast procedure (WLE vs. oncoplastic BCT vs. mastectomy) affected these outcomes and accounted for the low performance of Tc<jats:sup>99<\/jats:sup> (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). d-SLND resulted in a 28.1% total cost containment for women with pure DCIS on final pathology (4190 vs. 5828 USD, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Marking the SLN with SPIO may avoid overtreatment and allow for accurate d-SLND in patients with DCIS.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1245\/s10434-022-13064-0","type":"journal-article","created":{"date-parts":[[2023,1,31]],"date-time":"2023-01-31T14:05:48Z","timestamp":1675173948000},"page":"4064-4072","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Delayed Sentinel Lymph Node Dissection in Patients with a Preoperative Diagnosis of Ductal Cancer In Situ by Preoperative Injection with Superparamagnetic Iron Oxide (SPIO) Nanoparticles: The SentiNot Study"],"prefix":"10.1245","volume":"30","author":[{"given":"Andreas","family":"Karakatsanis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Staffan","family":"Eriksson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lida","family":"Pistiolis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Olofsson Bagge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyula","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Man","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ava","family":"Kwong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fredrik","family":"W\u00e4rnberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the SentiNot Trialists Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Imad","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdi Fatah","family":"Hersi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan","family":"Jazrawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helena","family":"Olofsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"St\u00e5lberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,1,31]]},"reference":[{"key":"13064_CR1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.f3289","author":"N Bundred","year":"2013","unstructured":"Bundred N, Dixon JM. Carcinoma in situ. BMJ. 2013. https:\/\/doi.org\/10.1136\/bmj.f3289.","journal-title":"BMJ"},{"key":"13064_CR2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.54.1177","author":"GH Lyman","year":"2014","unstructured":"Lyman GH, Temin S, Edge SB, et al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2014. https:\/\/doi.org\/10.1200\/JCO.2013.54.1177.","journal-title":"J Clin Oncol"},{"key":"13064_CR3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.71.0947","author":"GH Lyman","year":"2017","unstructured":"Lyman GH, Somerfield MR, Bosserman LD, Perkins CL, Weaver DL, Giuliano AE. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2017. https:\/\/doi.org\/10.1200\/JCO.2016.71.0947.","journal-title":"J Clin Oncol"},{"key":"13064_CR4","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz173","author":"F Cardoso","year":"2019","unstructured":"Cardoso F, Kyriakides S, Ohno S, et al. Early breast cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2019. https:\/\/doi.org\/10.1093\/annonc\/mdz173.","journal-title":"Ann Oncol"},{"issue":"30","key":"13064_CR5","doi-asserted-by":"publisher","first-page":"7703","DOI":"10.1200\/JCO.2005.08.001","volume":"23","author":"GH Lyman","year":"2005","unstructured":"Lyman GH, Giuliano AE, Somerfield MR, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005;23(30):7703\u201320. https:\/\/doi.org\/10.1200\/JCO.2005.08.001.","journal-title":"J Clin Oncol"},{"issue":"13","key":"13064_CR6","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1200\/JCO.2013.54.1177","volume":"32","author":"GH Lyman","year":"2014","unstructured":"Lyman GH, Temin S, Edge SB, et al. Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2014;32(13):1365\u201383. https:\/\/doi.org\/10.1200\/JCO.2013.54.1177.","journal-title":"J Clin Oncol"},{"key":"13064_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/S1072-7515(98)00306-8","author":"SM Feldman","year":"1999","unstructured":"Feldman SM, Krag DN, McNally RK, Moor BB, Weaver DL, Klein P. Limitation in gamma probe localization of the sentinel node in breast cancer patients with large excisional biopsy. J Am Coll Surg. 1999. https:\/\/doi.org\/10.1016\/S1072-7515(98)00306-8.","journal-title":"J Am Coll Surg"},{"key":"13064_CR8","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-016-3809-9","author":"A Karakatsanis","year":"2016","unstructured":"Karakatsanis A, Christiansen PM, Fischer L, et al. The Nordic SentiMag trial: a comparison of super paramagnetic iron oxide (SPIO) nanoparticles versus Tc99and patent blue in the detection of sentinel node (SN) in patients with breast cancer and a meta-analysis of earlier studies. Breast Cancer Res Treat. 2016. https:\/\/doi.org\/10.1007\/s10549-016-3809-9.","journal-title":"Breast Cancer Res Treat"},{"key":"13064_CR9","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.10606","author":"A Karakatsanis","year":"2017","unstructured":"Karakatsanis A, Daskalakis K, St\u00e5lberg P, et al. Superparamagnetic iron oxide nanoparticles as the sole method for sentinel node biopsy detection in patients with breast cancer. Br J Surg. 2017. https:\/\/doi.org\/10.1002\/bjs.10606.","journal-title":"Br J Surg"},{"key":"13064_CR10","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-019-07239-5","author":"F W\u00e4rnberg","year":"2019","unstructured":"W\u00e4rnberg F, Stigberg E, Obondo C, et al. Long-term outcome after retro-areolar versus peri-tumoral injection of superparamagnetic iron oxide nanoparticles (SPIO) for sentinel lymph node detection in breast cancer surgery. Ann Surg Oncol. 2019. https:\/\/doi.org\/10.1245\/s10434-019-07239-5.","journal-title":"Ann Surg Oncol"},{"key":"13064_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.11110","author":"A Karakatsanis","year":"2019","unstructured":"Karakatsanis A, Hersi AF, Pistiolis L, et al. Effect of preoperative injection of superparamagnetic iron oxide particles on rates of sentinel lymph node dissection in women undergoing surgery for ductal carcinoma in situ (SentiNot study). Br J Surg. 2019. https:\/\/doi.org\/10.1002\/bjs.11110.","journal-title":"Br J Surg"},{"key":"13064_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijnurstu.2014.09.006","author":"TA Lang","year":"2013","unstructured":"Lang TA, Altman DG. Basic statistical reporting for articles published in biomedical journals: the SAMPL guidelines. Int J Nurs Stud. 2013. https:\/\/doi.org\/10.1016\/j.ijnurstu.2014.09.006.","journal-title":"Int J Nurs Stud"},{"key":"13064_CR13","unstructured":"Uppsala University Hospital\/Uppsala Care. https:\/\/www.akademiska.se\/en\/for-patienter\/find-..-hospital-area\/uppsala-care\/"},{"key":"13064_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61602-X","author":"E von Elm","year":"2007","unstructured":"von Elm E, Altman DG, Egger M, Pocock SJ, G\u00f8tzsche PC, Vandenbroucke JP. The strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007. https:\/\/doi.org\/10.1016\/S0140-6736(07)61602-X.","journal-title":"Lancet"},{"key":"13064_CR15","doi-asserted-by":"publisher","first-page":"f1049","DOI":"10.1136\/bmj.f1049","volume":"346","author":"D Husereau","year":"2013","unstructured":"Husereau D, Drummond M, Petrou S, Carswell C, Moher D, Greenberg D, Augustovski F, Briggs AH, Mauskopf J. Consolidated health economic evaluation reporting standards (CHEERS) statement. BMJ. 2013;346:f1049.","journal-title":"BMJ"},{"issue":"11","key":"13064_CR16","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1111\/tbj.14070","volume":"26","author":"NF Baker","year":"2020","unstructured":"Baker NF, Baecher KM, Hart AM, Styblo TM, Carlson GW, Losken A. The impact of axillary node surgery on outcomes following immediate breast reconstruction. Breast J. 2020;26(11):2170\u20136. https:\/\/doi.org\/10.1111\/tbj.14070.","journal-title":"Breast J"},{"issue":"6","key":"13064_CR17","doi-asserted-by":"publisher","first-page":"1521","DOI":"10.1245\/s10434-018-6410-0","volume":"25","author":"BK Killelea","year":"2018","unstructured":"Killelea BK, Long JB, Dang W, et al. Associations between sentinel lymph node biopsy and complications for patients with ductal carcinoma in situ. Ann Surg Oncol. 2018;25(6):1521\u20139. https:\/\/doi.org\/10.1245\/s10434-018-6410-0.","journal-title":"Ann Surg Oncol."},{"issue":"3","key":"13064_CR18","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s10549-022-06540-4","volume":"192","author":"J Bogach","year":"2022","unstructured":"Bogach J, Cordeiro E, Reel E, Cil TD. Axillary surgery and complication rates after mastectomy and reconstruction for breast cancer: an analysis of the NSQIP database. Breast Cancer Res Treat. 2022;192(3):501\u20138. https:\/\/doi.org\/10.1007\/s10549-022-06540-4.","journal-title":"Breast Cancer Res Treat"},{"key":"13064_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/bjs.9337","author":"SK Lee","year":"2013","unstructured":"Lee SK, Yang JH, Woo SY, Lee JE, Nam SJ. Nomogram for predicting invasion in patients with a preoperative diagnosis of ductal carcinoma in situ of the breast. Br J Surg. 2013. https:\/\/doi.org\/10.1002\/bjs.9337.","journal-title":"Br J Surg."},{"issue":"15_suppl","key":"13064_CR20","doi-asserted-by":"publisher","first-page":"1595","DOI":"10.1200\/jco.2014.32.15_suppl.1595","volume":"32","author":"T Kondo","year":"2014","unstructured":"Kondo T, Hayashi N, Sachiko Ohde S, et al. A nomogram associated with high probability of invasive carcinoma on the surgical specimen in patients with preoperative diagnosis of ductal carcinoma in situ of the breast. J Clin Oncol. 2014;32:15_suppl:1595.","journal-title":"J Clin Oncol"},{"key":"13064_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.jamcollsurg.2004.11.012","author":"TWF Yen","year":"2005","unstructured":"Yen TWF, Hunt KK, Ross MI, et al. Predictors of invasive breast cancer in patients with an initial diagnosis of ductal carcinoma in situ: a guide to selective use of sentinel lymph node biopsy in management of ductal carcinoma in situ. J Am Coll Surg. 2005. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2004.11.012.","journal-title":"J Am Coll Surg"},{"key":"13064_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjsurg.2016.04.019","author":"Chehade H El Hage","year":"2017","unstructured":"El Hage Chehade H, Headon H, Wazir U, Abtar H, Kasem A, Mokbel K. Is sentinel lymph node biopsy indicated in patients with a diagnosis of ductal carcinoma in situ? A systematic literature review and meta-analysis. Am J Surg. 2017. https:\/\/doi.org\/10.1016\/j.amjsurg.2016.04.019.","journal-title":"Am J Surg"},{"key":"13064_CR23","doi-asserted-by":"publisher","DOI":"10.1093\/bjs\/znab149","author":"A Karakatsanis","year":"2021","unstructured":"Karakatsanis A, Charalampoudis P, Pistioli L, Di Micco R, Foukakis T, Valachis A. Axillary evaluation in ductal cancer in situ of the breast: Challenging the diagnostic accuracy of clinical practice guidelines. Br J Surg. 2021. https:\/\/doi.org\/10.1093\/bjs\/znab149.","journal-title":"Br J Surg"},{"key":"13064_CR24","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2015.0389","author":"EJ Coromilas","year":"2015","unstructured":"Coromilas EJ, Wright JD, Huang Y, et al. The influence of hospital and surgeon factors on the prevalence of axillary lymph node evaluation in ductal carcinoma in situ. JAMA Oncol. 2015. https:\/\/doi.org\/10.1001\/jamaoncol.2015.0389.","journal-title":"JAMA Oncol"},{"issue":"10 Pt A","key":"13064_CR25","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1016\/j.ejso.2020.05.028","volume":"46","author":"S van Bekkum","year":"2020","unstructured":"van Bekkum S, Ter Braak BPM, Plaisier PW, van Rosmalen J, Menke-Pluijmers MBE, Westenend PJ. Preoperative breast MRI in management of patients with needle biopsy-proven ductal\u00a0carcinoma in situ (DCIS). Eur J Surg Oncol. 2020;46(10 Pt A):1854\u201360. https:\/\/doi.org\/10.1016\/j.ejso.2020.05.028.","journal-title":"Eur J Surg Oncol"},{"key":"13064_CR26","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-017-6018-9","author":"LJ Grimm","year":"2017","unstructured":"Grimm LJ, Ryser MD, Partridge AH, et al. Surgical upstaging rates for vacuum-assisted biopsy proven DCIS: implications for active surveillance trials. Ann Surg Oncol. 2017. https:\/\/doi.org\/10.1245\/s10434-017-6018-9.","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"13064_CR27","doi-asserted-by":"publisher","first-page":"1337","DOI":"10.1016\/j.ejso.2013.09.028","volume":"39","author":"S Soumian","year":"2013","unstructured":"Soumian S, Verghese ET, Booth M, et al. Concordance between vacuum assisted biopsy and postoperative histology: implications for the proposed low risk DCIS trial (LORIS). Eur J Surg Oncol. 2013;39(12):1337\u201340. https:\/\/doi.org\/10.1016\/j.ejso.2013.09.028.","journal-title":"Eur J Surg Oncol"},{"issue":"3","key":"13064_CR28","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1148\/radiol.2016151947","volume":"281","author":"C Verheyden","year":"2016","unstructured":"Verheyden C, Pages-Bouic E, Balleyguier C, et al. Underestimation rate at MR imaging-guided vacuum-assisted breast biopsy: a multi-institutional retrospective study of 1509 breast biopsies. Radiology. 2016;281(3):708\u201319. https:\/\/doi.org\/10.1148\/radiol.2016151947.","journal-title":"Radiology"},{"key":"13064_CR29","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-015-4476-5","author":"C Tunon-de-Lara","year":"2015","unstructured":"Tunon-de-Lara C, Chauvet MP, Baranzelli MC, et al. The Role of sentinel lymph node biopsy and factors associated with invasion in extensive DCIS of the breast treated by mastectomy: the cinnamome prospective multicenter study. Ann Surg Oncol. 2015. https:\/\/doi.org\/10.1245\/s10434-015-4476-5.","journal-title":"Ann Surg Oncol."},{"key":"13064_CR30","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-015-4547-7","author":"AM Francis","year":"2015","unstructured":"Francis AM, Haugen CE, Grimes LM, et al. Is sentinel lymph node dissection warranted for patients with a diagnosis of ductal carcinoma in situ? Ann Surg Oncol. 2015. https:\/\/doi.org\/10.1245\/s10434-015-4547-7.","journal-title":"Ann Surg Oncol"},{"issue":"10","key":"13064_CR31","doi-asserted-by":"publisher","first-page":"3124","DOI":"10.1245\/s10434-019-07556-9","volume":"26","author":"CD Champion","year":"2019","unstructured":"Champion CD, Ren Y, Thomas SM, et al. DCIS with microinvasion: is it in situ or invasive disease? Ann Surg Oncol. 2019;26(10):3124\u201332. https:\/\/doi.org\/10.1245\/s10434-019-07556-9.","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"13064_CR32","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1002\/bjs.11079","volume":"106","author":"F Magnoni","year":"2019","unstructured":"Magnoni F, Massari G, Santomauro G, et al. Sentinel lymph node biopsy in microinvasive ductal carcinoma in situ. Br J Surg. 2019;106(4):375\u201383. https:\/\/doi.org\/10.1002\/bjs.11079.","journal-title":"Br J Surg"},{"key":"13064_CR33","doi-asserted-by":"publisher","DOI":"10.1002\/jso.20670","author":"M Intra","year":"2007","unstructured":"Intra M, Veronesi P, Gentilini OD, et al. Sentinel lymph node biopsy is feasible even after total mastectomy. J Surg Oncol. 2007. https:\/\/doi.org\/10.1002\/jso.20670.","journal-title":"J Surg Oncol"},{"key":"13064_CR34","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-016-5688-z","author":"KK Hunt","year":"2017","unstructured":"Hunt KK, Euhus DM, Boughey JC, et al. Society of surgical oncology breast disease working group statement on prophylactic (risk-reducing) mastectomy. Ann Surg Oncol. 2017. https:\/\/doi.org\/10.1245\/s10434-016-5688-z.","journal-title":"Ann Surg Oncol"},{"key":"13064_CR35","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-015-4660-7","author":"LM Erdahl","year":"2016","unstructured":"Erdahl LM, Boughey JC, Hoskin TL, Degnim AC, Hieken TJ. Contralateral prophylactic mastectomy: factors predictive of occult malignancy or high-risk lesion and the impact of MRI and genetic testing. Ann Surg Oncol. 2016. https:\/\/doi.org\/10.1245\/s10434-015-4660-7.","journal-title":"Ann Surg Oncol"},{"key":"13064_CR36","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-018-4953-1","author":"H Yamauchi","year":"2018","unstructured":"Yamauchi H, Okawa M, Yokoyama S, et al. High rate of occult cancer found in prophylactic mastectomy specimens despite thorough presurgical assessment with MRI and ultrasound: findings from the hereditary breast and ovarian cancer registration 2016 in Japan. Breast Cancer Res Treat. 2018. https:\/\/doi.org\/10.1007\/s10549-018-4953-1.","journal-title":"Breast Cancer Res Treat"},{"issue":"2","key":"13064_CR37","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1056\/NEJM199901143400201","volume":"340","author":"LC Hartmann","year":"1999","unstructured":"Hartmann LC, Schaid DJ, Woods JE, et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N Engl J Med. 1999;340(2):77\u201384. https:\/\/doi.org\/10.1056\/NEJM199901143400201.","journal-title":"N Engl J Med"},{"key":"13064_CR38","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.0839","author":"C Kuhl","year":"2010","unstructured":"Kuhl C, Weigel S, Schrading S, et al. Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial. J Clin Oncol. 2010. https:\/\/doi.org\/10.1200\/JCO.2009.23.0839.","journal-title":"J Clin Oncol"},{"key":"13064_CR39","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-017-5925-0","author":"BL Murphy","year":"2017","unstructured":"Murphy BL, Glasgow AE, Keeney GL, Habermann EB, Boughey JC. Selective use of sentinel lymph node surgery in patients undergoing prophylactic mastectomy using intraoperative pathology. Ann Surg Oncol. 2017. https:\/\/doi.org\/10.1245\/s10434-017-5925-0.","journal-title":"Ann Surg Oncol"},{"key":"13064_CR40","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-016-3783-2","author":"LM van Roozendaal","year":"2016","unstructured":"van Roozendaal LM, Goorts B, Klinkert M, et al. Sentinel lymph node biopsy can be omitted in DCIS patients treated with breast conserving therapy. Breast Cancer Res Treat. 2016. https:\/\/doi.org\/10.1007\/s10549-016-3783-2.","journal-title":"Breast Cancer Res Treat"},{"key":"13064_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2016.04.006","author":"C Renaudeau","year":"2016","unstructured":"Renaudeau C, Lefebvre-Lacoeuille C, Campion L, et al. Evaluation of sentinel lymph node biopsy after previous breast surgery for breast cancer: GATA study. Breast. 2016. https:\/\/doi.org\/10.1016\/j.breast.2016.04.006.","journal-title":"Breast"},{"issue":"2","key":"13064_CR42","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1007\/S13193-018-0861-4","volume":"10","author":"SK Agrawal","year":"2019","unstructured":"Agrawal SK, Bansawal L, Arun I, Datta SS, Chatterjee S, Ahmed R. Sentinel lymph node biopsy after initial lumpectomy (SNAIL Study)\u2014a prospective validation study. Indian J Surg Oncol. 2019;10(2):350\u20136. https:\/\/doi.org\/10.1007\/S13193-018-0861-4.","journal-title":"Indian J Surg Oncol"},{"issue":"5","key":"13064_CR43","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1245\/s10434-016-5135-1","volume":"23","author":"M Teshome","year":"2016","unstructured":"Teshome M, Wei C, Hunt KK, Thompson A, Rodriguez K, Mittendorf EA. Use of a magnetic tracer for sentinel lymph node detection in early-stage breast cancer patients: a meta-analysis. Ann Surg Oncol. 2016;23(5):1508\u201314. https:\/\/doi.org\/10.1245\/s10434-016-5135-1.","journal-title":"Ann Surg Oncol"},{"key":"13064_CR44","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-019-07577-4","author":"MD Alvarado","year":"2019","unstructured":"Alvarado MD, Mittendorf EA, Teshome M, et al. SentimagIC: a non-inferiority trial comparing superparamagnetic iron oxide versus Technetium-99m and blue dye in the detection of axillary sentinel nodes in patients with early-stage breast cancer. Ann Surg Oncol. 2019. https:\/\/doi.org\/10.1245\/s10434-019-07577-4.","journal-title":"Ann Surg Oncol"},{"key":"13064_CR45","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040693","author":"AF Hersi","year":"2021","unstructured":"Hersi AF, Pistiolis L, Luberth CD, et al. Article optimizing dose and timing in magnetic tracer techniques for sentinel lymph node detection in early breast cancers: the prospective multicenter sentidose trial. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13040693.","journal-title":"Cancers (Basel)"},{"issue":"2","key":"13064_CR46","doi-asserted-by":"publisher","first-page":"e45","DOI":"10.1016\/j.ejso.2021.12.401","volume":"48","author":"A Karakatsanis","year":"2022","unstructured":"Karakatsanis A, Pantiora E, Tasoulis MK, Valachis A, Rubio I. The evolution and refinement of magnetic-guided sentinel lymph node detection in breast cancer. A systematic review and meta-analysis. Eur J Surg Oncol. 2022;48(2):e45\u20136. https:\/\/doi.org\/10.1016\/j.ejso.2021.12.401.","journal-title":"Eur J Surg Oncol"},{"issue":"9","key":"13064_CR47","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.1002\/bjs.5763","volume":"94","author":"SH Estourgie","year":"2007","unstructured":"Estourgie SH, Vald\u00e9s Olmos RA, Nieweg OE, Hoefnagel CA, Rutgers EJT, Kroon BBR. Excision biopsy of breast lesions changes the pattern of lymphatic drainage. Br J Surg. 2007;94(9):1088\u201391. https:\/\/doi.org\/10.1002\/bjs.5763.","journal-title":"Br J Surg"},{"key":"13064_CR48","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2016.08.006","author":"L Zetterlund","year":"2016","unstructured":"Zetterlund L, Gabrielson S, Axelsson R, et al. Impact of previous surgery on sentinel lymph node mapping: hybrid SPECT\/CT before and after a unilateral diagnostic breast excision. Breast. 2016. https:\/\/doi.org\/10.1016\/j.breast.2016.08.006.","journal-title":"Breast"},{"key":"13064_CR49","unstructured":"SSO\u2014Sentinel node biopsy in node negative women 70 and over. Choosing Wisely. Accessed 11 Feb 2021. https:\/\/www.choosingwisely.org\/clinician-lists\/sso-sentinel-node-biopsy-in-node-negative-women-70-and-over\/"},{"key":"13064_CR50","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13174285","author":"A Jazrawi","year":"2021","unstructured":"Jazrawi A, Pantiora E, Abdsaleh S, et al. Magnetic-Guided Axillary UltraSound (MagUS) sentinel lymph node biopsy and mapping in patients with early breast cancer A phase 2, single-arm prospective clinical trial. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13174285.","journal-title":"Cancers (Basel)"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-022-13064-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-022-13064-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-022-13064-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,8]],"date-time":"2023-06-08T13:03:00Z","timestamp":1686229380000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-022-13064-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1,31]]},"references-count":50,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2023,7]]}},"alternative-id":["13064"],"URL":"https:\/\/doi.org\/10.1245\/s10434-022-13064-0","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,1,31]]},"assertion":[{"value":"1 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 January 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"ROB has received institutional research grants from Bristol-Myers Squibb (BMS) and SkyLineDx, speaker honorarium from Roche and Pfizer and has served on advisory boards for Amgen, BD\/BARD, Bristol-Myers Squibb (BMS), Merck Sharp & Dohme (MSD), Novartis, Roche and Sanofi Genzyme. All other authors declare no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}